Article PDF
References
Bellgrau, D. et al. Nature 377, 630–632 (1995).
Vaux, D. L. Nature 377, 576–577 (1995).
Kayagaki, N. et al. J. exp. Med 182, 1777–1783 (1995).
Abreu-Martin, M. T. et al. J. Immun. 155, 4147–4154 (1995).
Iwai, K. et al. Blood 84, 1201–1208 (1994).
Tanaka, M. et al. EMBO J. 14, 1129–1135 (1995).
Sullivan, F. P. et al. Transplantation 44, 465–468 (1987).
Kemp, C. B. et al. Diabetologia 9, 486–491 (1973).
Ogasawara, J. et al. Nature 364, 806–809 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yagita, H., Seino, Ki., Kayagaki, N. et al. CD95 ligand in graft rejection. Nature 379, 682 (1996). https://doi.org/10.1038/379682a0
Issue Date:
DOI: https://doi.org/10.1038/379682a0
This article is cited by
-
An Update on the Pathogenesis of Skin Damage in Lupus
Current Rheumatology Reports (2020)
-
CD95 and CD95L promote and protect cancer stem cells
Nature Communications (2014)
-
Tumor counterattack: fact or fiction?
Cancer Immunology, Immunotherapy (2005)
-
Local adenoviral expression of Fas ligand upregulates pro-inflammatory immune responses in the CNS
Gene Therapy (2004)
-
The role of Fas ligand in immune privilege
Nature Reviews Molecular Cell Biology (2001)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.